Following The Announcement By Asahi Kasei That It Controls Over 90% Of Calliditas Therapeutics Has Resolved To Apply For Delisting Its Common Shares From Nasdaq Stockholm And Its American Depositary Shares From The Nasdaq Global Select Market
Following The Announcement By Asahi Kasei That It Controls Over 90% Of Calliditas Therapeutics Has Resolved To Apply For Delisting Its Common Shares From Nasdaq Stockholm And Its American Depositary Shares From The Nasdaq Global Select Market
隨着旭化成宣佈控制超過90%的calliditas therapeutics，決定申請將其普通股票從納斯達克斯德哥爾摩市場退市，並將其美國存託憑證從納斯達克全球精選市場退市。
Following The Announcement By Asahi Kasei That It Controls Over 90% Of Calliditas Therapeutics Has Resolved To Apply For Delisting Its Common Shares From Nasdaq Stockholm And Its American Depositary Shares From The Nasdaq Global Select Market
在朝日化成宣佈控制超過90％的Calliditas Therapeutics之後，Therapeutics決定申請將其普通股從斯德哥爾摩納斯達克退市，將其美國存托股從納斯達克全球精選市場退市